Quantel Medical has announced it has received approval from the U.S. Food and Drug Administration (FDA) on March 25, 2019 for the New A/B/S Ultrasound Platform: ABSolu®.
“ABSolu® is our new ultrasound platform replacing our flagship ultrasound system Aviso. It is the achievement of years of work carried out by our R&D Department in collaboration with ultrasound specialists and we can say that once again, we are setting new standards in ophthalmic ultrasound imaging” said Jean-Marc Gendre, CEO of Quantel Medical. “For ophthalmologists looking for excellence in ultrasound imaging, ABSolu® is the ideal partner in their everyday practice.”
Technological breakthroughs in the ABSolu® include:
- A new 5 ring annular technology 20MHz B probe that increases the depth of field by 70% thus offering in a single scan high definition information of the vitreous, retinal wall and orbit. ABSolu® also features standardized A Mode that complies with all the hardware and software requirements necessary for proper tissue characterization essential for tumor diagnosis as per the requirements of Prof. K. Ossoinig.
- Motion sensors have been integrated in all B Mode and UBM probes allowing for an automatic and constant detection of the probe position and ultrasound beam direction (patented technology). A new signal processing for the linear 50 MHz UBM to offer high image quality of the anterior chamber and lens.
- A new full HD screen compliant with section 14 of the DICOM standard, a world premiere in ophthalmic ultrasound.
At the upcoming ASCRS Congress, to be held in San Diego May 03-07, the attendees will have the possibility to get a full review of the new ABSolu® Ultrasound Platform with its 5 ring annular technology 20MHz B probe and get additional information in exhibit booth #631.
Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases.
Learn more about ophthalmic ultrasound systems here.